S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

LXRX Lexicon Pharmaceuticals Inc

0.7399

0.0264 (3.70%)

11 Feb 2025 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Lexicon Pharmaceuticals Charts.

Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Lexicon Pharmaceuticals Charts.

Lexicon Pharmaceuticals Inc News

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Wednesday 22 January 2025 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 8 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 3 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Friday 3 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 3 January 2025 (1 month ago) • Edgar (US Regulatory)

Lexicon Appoints Scott Coiante as Chief Financial Officer
Friday 3 January 2025 (1 month ago) • GlobeNewswire Inc.

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)
Saturday 21 December 2024 (2 months ago) • GlobeNewswire Inc.

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Tuesday 10 December 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 3 December 2024 (2 months ago) • Edgar (US Regulatory)

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)
Wednesday 27 November 2024 (3 months ago) • GlobeNewswire Inc.

Lexicon Pharmaceuticals to Participate in December Investor Conferences
Tuesday 26 November 2024 (3 months ago) • GlobeNewswire Inc.

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
Friday 22 November 2024 (3 months ago) • GlobeNewswire Inc.

More Lexicon Pharmaceuticals Inc News Articles

TRIUNFO PART ON

BNP Paribas Issuance

Axa Im Act Biodiversity ...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions